Market news

AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain. Poster Presentation Title: Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation s

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will present at the following investor conferences in September. 2026 Cantor Global Healthcare Conference Date & Time: Friday, September 11, 2026, at 8:00 a.m. ETLocation: New York,

Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.

Tipranks Press Release.

Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026 AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indicat

Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026Successfully completed oversubscribed $57.5 million public offering supported by both new and existing healthcare-focused investors AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orpha

Data support ongoing Phase 2 “RENEW” trialFirst-in-human clinical study produced measurable reductions in multiple markers of lung scarring and inflammation in IPF patientsStudy confirms LTI-03 was safe and well-tolerated AUSTIN, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced pu

Detailed price information for Rein Therapeutics Inc (RNTX-Q) from The Globe and Mail including charting and trades.

Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary FibrosisCompany on track to report initial topline data in 2H 2026 AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced that its Phase 2 RENEW clinical trial is now open and enro

BOSTON, July 13, 2026--Celea Therapeutics Doses First Patient in Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis